ArticleSage open pathology
Comparative Expression of MDM2, SOX2, and Ki-67 in Oral and Cutaneous Lichen Planus: Implications for Malignant Potential.
Article in Sage open pathology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aim: Oral lichen planus (OLP) is a chronic inflammatory disease that can show potential for malignant transformation, unlike cutaneous lichen planus (CLP). The exact molecular reasons behind this difference are not well known. This study aimed to evaluate the expression of 3 biomarkers namely MDM2, SOX2, and Ki-67 in OLP and CLP to assess their relationship with cell proliferation and possible malignant potential. Methods: This retrospective study was carried out at Sina Hospital in Tabriz, Iran, from April 2022 to June 2023. Fifty paraffin-embedded tissue samples were analyzed, including 25 oral and 25 cutaneous lichen planus cases. Sections were stained immunohistochemically for MDM2, SOX2, and Ki-67. Two pathologists, blinded to patient information, evaluated the slides. Expression was classified as negative, low, or high. Data were analyzed in SPSS version 26 using descriptive statistics and Fisher's Exact Test, with a Results: In CLP, all samples were negative for Ki-67, while SOX2 and MDM2 were positive at low levels in only 8% of cases. In OLP, Ki-67 was low in 16%, SOX2 in 20%, and MDM2 was high in 40% of samples. A significant correlation among the 3 markers was seen in OLP ( Conclusion: OLP, especially its erosive form, shows higher molecular activity compared with CLP. The coordinated expression of MDM2, SOX2, and Ki-67 supports their role in cell proliferation and malignant potential. MDM2, in particular, may serve as an early indicator for identifying OLP cases at higher risk of malignant transformation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.